The Sunday Plenary will feature a wealth of scientific lectures addressing the influence of genetics on skin disease, tumescent drug delivery, how gene networks influence skin cancer, neurological causes of itch, and HIV/AIDS.
The Plenary also will feature addresses by AAD President Mark Lebwohl, MD, and President-Elect Abel Torres, MD, JD, from 8 to 11:30 a.m. in Hall D.
Clarence S. Livingood, MD, Award and Lectureship
Amy S. Paller, MD, will present “Bedside to Bench and Back to the Bedside” in which she will discuss research advances that can improve outcomes for patients with skin disease. She is the chair of the department of dermatology and the Walter J. Hamlin Professor of Dermatology, and a professor of dermatology and pediatrics at Northwestern University Feinberg School of Medicine.
Dr. Paller will explain how decoding the genetic, epigenetic, and transcriptomic features of both common and rare skin disease is defining new phenotype classifications. It also has led to the development of pathogenesis-based therapies to help track how intervention normalizes biological function.
Eugene J. Van Scott Award for Innovative Therapy of the Skin and Phillip Frost Leadership Lecture
Jeffrey A. Klein, MD, will present “Tumescent Drug Delivery: Lidocaine & Beyond” in which he will review how tumescent antimicrobial delivery (TAD) helps reduce surgical site infections. He is a dermatologic surgeon from San Juan Capistrano, California, and a clinical professor at the University of California, Irvine.
Dr. Klein led the development of liposuction using tumescent lidocaine anesthesia, which has been expanded for other treatment options that have been remarkably safe and efficient.
Lila and Murray Gruber Memorial Cancer Research Award and Lectureship
Paul A. Khavari, MD, PhD, will explain how advances in genome technology have enabled new insights into the development of common skin cancers in “Pathogenesis of Skin Cancer.” He is chair of the department of dermatology at Stanford University School of Medicine and co-director of the Stanford Program in Epithelial Biology.
Cancers such as squamous cell carcinoma, basal cell carcinoma, and malignant melanoma are characterized by disruption of specific gene networks that are important in normal skin development and health. He will discuss how identification of those networks is providing new insights into skin cancer prevention and therapy.
Marion B. Sulzberger, MD, Memorial Award and Lectureship
Gil Yosipovitch, MD, will share his years of research when he presents “Itch.” He is chair and professor of the department of dermatology at Lewis Katz School of Medicine, Temple University.
Dr. Yosipovitch will discuss increased knowledge of neurological causes of itch. Many itches, such as pruritis, result from interactions between nerves connecting the skin to the brain. In chronic itch, the neural pathways of itch may be rewired and overamplified.
Anthony S. Fauci, MD, director of the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health will present “Ending the HIV/AIDS Pandemic: An Achievable Goal.”
Since his appointment as NIAID director in 1984, Dr. Fauci has overseen an extensive research portfolio devoted to preventing, diagnosing, and treating infectious and immune-mediated diseases.